In June, GE revealed plans to separate its healthcare business into a standalone enterprise. The healthcare unit generated 15.8 percent of GE’s total sales and 43.2 percent of its total operating profit in 2017.
CFRA research equity analyst Jim Corridore told CNBC that Lawrence Culp, the former CEO of Danaher who will take over for Mr. Flannery at GE, may decide whether the company follows through on its plans to spin off the healthcare entity.
“Maybe healthcare is not going to get spun off now,” Mr. Corridore told CNBC. “Maybe some of the parts that were going to be sold make more sense today.”
A GE Healthcare spokesperson said the unit “plans to continue working toward separation of GE” and Mr. Flannery’s removal “does not change what’s happening at GE Healthcare.” GE also said it remains “committed to establishing healthcare as a separate independent entity.”
Mr. Flannery’s removal reportedly stemmed from the board’s frustration with the slow pace of change under his leadership, sources familiar with the matter told CNBC.
More articles on health IT:
CHI Franciscan, GE partner to implement AI-powered command center
ECRI: Top 10 health IT hazards for 2019
Michigan Medicine may have exposed 3.7K patients’ contact information during fundraising campaign
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
